We’ve developed the GlycoVision™ platform to exponentially improve the speed, scope, and scale of glycoproteomics, thereby enabling new insights into biomarker discovery, disease detection and progression, therapeutic response, and monitoring.
A new era of precision medicine is here.
At InterVenn Biosciences, we’ve leveraged our proprietary AI-driven platform to unlock the glycoproteome with unparalleled detail, allowing us to explore this untapped layer of biology on a clinically meaningful scale for the first time in history.
Glycosylation of proteins controls the activation state of immune cells and can distinguish specific physiological states. By exploring how proteins are glycosylated and how these modifications affect protein function, we can uncover invaluable insights into the molecular mechanisms underlying health and disease.
Once available, GlycoKnow™ Colon will be a blood-based laboratory-developed test that measures the body’s early response to colorectal cancer progression. Powered by Glycovision, GlycoKnow Colon assesses the presence of adenomas with high-grade dysplasia or colorectal cancer, empowering healthcare professionals to take action before the onset of disease, when intervention is most optimal.
We are a life sciences company founded on the belief that no one should ever be blindsided by disease. We aim to expand the -omics universe by harnessing the power of the glycoproteome - ushering in a new era of personalized, predictive, and preventive care.
Decoding the glycoproteome: a new frontier for biomarker discovery in cancer
Journal of Hematology & Oncology | March 22, 2024
Early Detection of Advanced Adenomas and Colorectal Carcinoma by Serum Glycoproteome Profiling
Gastroenterology | September 25, 2023
Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors
Frontier in Immunology | June 13, 2023
2 Tower Place, 5th Floor,
South San Francisco, CA 94080
Bay Area Lab
